Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.

[1]  E. Thiel,et al.  Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. , 2008, Human pathology.

[2]  P. Altevogt,et al.  Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. , 2008, Kidney international.

[3]  B. Kreike,et al.  The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. , 2008, Cancer research.

[4]  J. Daniel,et al.  A Role for the Cleaved Cytoplasmic Domain of E-cadherin in the Nucleus*S⃞ , 2008, Journal of Biological Chemistry.

[5]  H. Mehdorn,et al.  Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas , 2008, Glia.

[6]  J. Imura,et al.  Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer , 2008, British Journal of Cancer.

[7]  Jianhua Wang,et al.  CXCL16 Functions as a Novel Chemotactic Factor for Prostate Cancer Cells In vitro , 2008, Molecular Cancer Research.

[8]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[9]  N. Clarke,et al.  Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma , 2008, British Journal of Cancer.

[10]  L. Costa,et al.  Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. , 2007, The oncologist.

[11]  C. Weber,et al.  Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by α- and γ-secretases , 2007 .

[12]  C. Weber,et al.  Regulated Shedding of Transmembrane Chemokines by the Disintegrin and Metalloproteinase 10 Facilitates Detachment of Adherent Leukocytes1 , 2007, The Journal of Immunology.

[13]  Felix Scholz,et al.  Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. , 2007, The Journal of investigative dermatology.

[14]  K. Tsuneyama,et al.  High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. , 2007, Cancer research.

[15]  B. Drucker,et al.  Renal cell carcinoma: current status and future prospects. , 2005, Cancer treatment reviews.

[16]  Y. Tsutsumi,et al.  Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. , 2005, Biological & pharmaceutical bulletin.

[17]  K. Reiss,et al.  Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells , 2005, Journal of neurochemistry.

[18]  M. Miyasaka,et al.  Chemokines in tumor progression and metastasis , 2005, Cancer science.

[19]  M. Lambert,et al.  Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. , 2005, Combinatorial chemistry & high throughput screening.

[20]  D. Wågsäter,et al.  Expression of CXCL16 in human rectal cancer. , 2004, International journal of molecular medicine.

[21]  S. Rose-John,et al.  The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-γ and TNF-α and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10 1 , 2004, The Journal of Immunology.

[22]  T. Kita,et al.  Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.

[23]  M. Huang,et al.  SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10 , 2003, Molecular Cancer.

[24]  R. Nibbs,et al.  The Chemokine ESkine/CCL27 Displays Novel Modes of Intracrine and Paracrine Function1 , 2002, The Journal of Immunology.

[25]  P. Altevogt,et al.  Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins , 2001, The Journal of cell biology.

[26]  M Dietel,et al.  Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. , 2001, The American journal of pathology.

[27]  A. Belldegrun,et al.  The changing natural history of renal cell carcinoma. , 2001, The Journal of urology.

[28]  Jos Tournoy,et al.  Implication of APP secretases in notch signaling , 2001, Journal of Molecular Neuroscience.

[29]  S. Petersen,et al.  Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. , 2001, European journal of cancer.

[30]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[31]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[32]  P. Schellhammer,et al.  Spontaneous regression of metastatic renal cell carcinoma. , 1982, Urology.

[33]  M. Atkins,et al.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Schmidt-Zachmann,et al.  Molecular characterization of a novel, widespread nuclear protein that colocalizes with spliceosome components. , 1998, Molecular biology of the cell.